FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3111923710> ?p ?o ?g. }

• W3111923710 endingPage "iii419" @default.
• W3111923710 startingPage "iii419" @default.
• W3111923710 abstract "Abstract INTRODUCTION Because treatment and clinical management decisions for children with NF1-OPG remain challenging, we sought to establish evidence-based guidelines. We prospectively enrolled children with newly-diagnosed NF1-OPGs, and gathered standardized clinical neuro-oncology and ophthalmology assessments. METHODS Only children with NF1 and newly diagnosed OPGs, confirmed by central review, were eligible. Indications for obtaining the initial MRI, as well as factors associated with the decision to treat with chemotherapy or observe without treatment, were obtained. Quantitative visual acuity (VA), other ophthalmic features, and imaging were captured at standard time points. Goal enrollment is 250 subjects. RESULTS One-hundred thirty-three children (52% female) from 20 institutions met inclusion criteria, and were included in this preliminary analysis. Eighty-six percent of subjects were able to perform quantitative VA testing at enrollment. The most common reasons for the diagnostic MRI included screening related to NF1 diagnosis (36.8%), ophthalmologic concerns (29.3%), and non-ophthalmologic concerns (24.8%), such as headache. To date, twenty subjects have initiated treatment with chemotherapy, twelve (9%) at the time of the initial OPG diagnosis. Median age at OPG diagnosis was 3.1 years. Age and sex distribution were similar in subjects immediately entering the observation and treatment arms (median age 3.0 versus 3.5 years, respectively). CONCLUSION Most children with NF1-OPGs are observed at time of their initial OPG diagnosis, rather than treated. Importantly, a large proportion of children are able to complete quantitative VA testing at enrollment. Once enrollment is complete, these data will help to establish evidence-based guidelines for clinical management of NF1-OPGs." @default.
• W3111923710 created "2020-12-21" @default.
• W3111923710 creator A5000749732 @default.
• W3111923710 creator A5000984171 @default.
• W3111923710 creator A5002191021 @default.
• W3111923710 creator A5003613062 @default.
• W3111923710 creator A5004507996 @default.
• W3111923710 creator A5006903754 @default.
• W3111923710 creator A5010655268 @default.
• W3111923710 creator A5012955659 @default.
• W3111923710 creator A5013176549 @default.
• W3111923710 creator A5014921835 @default.
• W3111923710 creator A5015509300 @default.
• W3111923710 creator A5016983624 @default.
• W3111923710 creator A5017960939 @default.
• W3111923710 creator A5020501657 @default.
• W3111923710 creator A5021151494 @default.
• W3111923710 creator A5023317256 @default.
• W3111923710 creator A5024777890 @default.
• W3111923710 creator A5026021396 @default.
• W3111923710 creator A5027583936 @default.
• W3111923710 creator A5032954251 @default.
• W3111923710 creator A5035196921 @default.
• W3111923710 creator A5039203910 @default.
• W3111923710 creator A5043546185 @default.
• W3111923710 creator A5044018710 @default.
• W3111923710 creator A5044892740 @default.
• W3111923710 creator A5045064484 @default.
• W3111923710 creator A5050629531 @default.
• W3111923710 creator A5050789703 @default.
• W3111923710 creator A5057717799 @default.
• W3111923710 creator A5059041120 @default.
• W3111923710 creator A5061441245 @default.
• W3111923710 creator A5062314473 @default.
• W3111923710 creator A5065249298 @default.
• W3111923710 creator A5066034372 @default.
• W3111923710 creator A5067762141 @default.
• W3111923710 creator A5068257880 @default.
• W3111923710 creator A5070433600 @default.
• W3111923710 creator A5071642692 @default.
• W3111923710 creator A5077621447 @default.
• W3111923710 creator A5081965993 @default.
• W3111923710 creator A5082334822 @default.
• W3111923710 creator A5083585208 @default.
• W3111923710 creator A5084930644 @default.
• W3111923710 creator A5090178491 @default.
• W3111923710 creator A5091441085 @default.
• W3111923710 creator A5051120368 @default.
• W3111923710 date "2020-12-01" @default.
• W3111923710 modified "2023-10-16" @default.
• W3111923710 title "NFB-09. ENROLLMENT AND CLINICAL CHARACTERISTICS OF NEWLY DIAGNOSED, NEUROFIBROMATOSIS TYPE 1 ASSOCIATED OPTIC PATHWAY GLIOMA (NF1-OPG): PRELIMINARY RESULTS FROM AN INTERNATIONAL MULTI-CENTER NATURAL HISTORY STUDY" @default.
• W3111923710 doi "https://doi.org/10.1093/neuonc/noaa222.613" @default.
• W3111923710 hasPublicationYear "2020" @default.
• W3111923710 type Work @default.
• W3111923710 sameAs 3111923710 @default.
• W3111923710 citedByCount "2" @default.
• W3111923710 countsByYear W31119237102023 @default.
• W3111923710 crossrefType "journal-article" @default.
• W3111923710 hasAuthorship W3111923710A5000749732 @default.
• W3111923710 hasAuthorship W3111923710A5000984171 @default.
• W3111923710 hasAuthorship W3111923710A5002191021 @default.
• W3111923710 hasAuthorship W3111923710A5003613062 @default.
• W3111923710 hasAuthorship W3111923710A5004507996 @default.
• W3111923710 hasAuthorship W3111923710A5006903754 @default.
• W3111923710 hasAuthorship W3111923710A5010655268 @default.
• W3111923710 hasAuthorship W3111923710A5012955659 @default.
• W3111923710 hasAuthorship W3111923710A5013176549 @default.
• W3111923710 hasAuthorship W3111923710A5014921835 @default.
• W3111923710 hasAuthorship W3111923710A5015509300 @default.
• W3111923710 hasAuthorship W3111923710A5016983624 @default.
• W3111923710 hasAuthorship W3111923710A5017960939 @default.
• W3111923710 hasAuthorship W3111923710A5020501657 @default.
• W3111923710 hasAuthorship W3111923710A5021151494 @default.
• W3111923710 hasAuthorship W3111923710A5023317256 @default.
• W3111923710 hasAuthorship W3111923710A5024777890 @default.
• W3111923710 hasAuthorship W3111923710A5026021396 @default.
• W3111923710 hasAuthorship W3111923710A5027583936 @default.
• W3111923710 hasAuthorship W3111923710A5032954251 @default.
• W3111923710 hasAuthorship W3111923710A5035196921 @default.
• W3111923710 hasAuthorship W3111923710A5039203910 @default.
• W3111923710 hasAuthorship W3111923710A5043546185 @default.
• W3111923710 hasAuthorship W3111923710A5044018710 @default.
• W3111923710 hasAuthorship W3111923710A5044892740 @default.
• W3111923710 hasAuthorship W3111923710A5045064484 @default.
• W3111923710 hasAuthorship W3111923710A5050629531 @default.
• W3111923710 hasAuthorship W3111923710A5050789703 @default.
• W3111923710 hasAuthorship W3111923710A5051120368 @default.
• W3111923710 hasAuthorship W3111923710A5057717799 @default.
• W3111923710 hasAuthorship W3111923710A5059041120 @default.
• W3111923710 hasAuthorship W3111923710A5061441245 @default.
• W3111923710 hasAuthorship W3111923710A5062314473 @default.
• W3111923710 hasAuthorship W3111923710A5065249298 @default.
• W3111923710 hasAuthorship W3111923710A5066034372 @default.
• W3111923710 hasAuthorship W3111923710A5067762141 @default.
• W3111923710 hasAuthorship W3111923710A5068257880 @default.
• W3111923710 hasAuthorship W3111923710A5070433600 @default.
• W3111923710 hasAuthorship W3111923710A5071642692 @default.
• W3111923710 hasAuthorship W3111923710A5077621447 @default.

• next